According to reports, Biologics is considering an initial public offering (IPO) in Hong Kong. This move aims to raise capital for further business expansion. The exact timing and scale of the IPO have not been disclosed yet. Analysts suggest that this decision aligns with the company's global strategic development goals.

免责声明：本文内容由开放的智能模型自动生成，仅供参考。